Multiple growth levers make Cadila Healthcare attractive on the Street

HCQ supplies for Covid-19 treatment to propel US growth, even as domestic pharma and consumer businesses are in a sweet spot

Shares of Cadila Healthcare, which had seen a lacklustre trend for almost a year before the revival a fortnight back, have surged more than 28 per cent in two days.
 

The stock scaled its 52-week high of Rs 366.55 in intra-day trade on Wednesday, before closing at Rs 350. Street sentiment has improved of late, given that the company is expected to benefit from hydroxychloroquine (HCQ) supplies to the US.

A company spokesperson said monthly HCQ production had already been ramped up from 3 tonnes to 20-30 tonnes (more than 100 million tablets) to meet requirements. In addition, Cadila will scale